Enrolling by invitationInterventionalNot ApplicableUpdated May 6, 2026
Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to... | NCT02208258 | Trialant
WithdrawnInterventionalNot ApplicableUpdated Jan 29, 2016
Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.
ClinicalTrials.gov ID
NCT02208258
Lead Sponsor
Consure Medical Pvt. Ltd.INDUSTRY
Overall Status
Withdrawn
Study Type
Interventional
Phase
Not Applicable
Enrollment
0Actual
Last Update Posted
Jan 29, 2016Estimated
Start Date
Sep 2014
Primary Completion Date
Oct 2014Actual
Completion Date
Oct 2014Actual
Brief Summary
The purpose of this study is to evaluate the safety, efficacy, and functionality of the Consure 120 Stool Management System in hospitalized bedridden patients suffering from fecal incontinence.
Fecal Incontinence
Consure 120 Stool Management System
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients, more than 18 years of age incontinent with liquid to semi-formed stool.
Non-ambulatory, hospitalized patients.
History of passage of at least 1 stool in 24 hours.
Exclusion Criteria:
Patients with suspected or confirmed rectal mucosal impairment or pathology.
Patients with have undergone descending colon or rectal surgery within the preceding six months.
Patients with significant hemorrhoids, growth, fissure, stricture, stenosis or local pathology (either benign and malignant) as observed during rectal examination.
Patients suspected to have impacted stool or is suffering from constipation.
Patients with confirmed pregnancy or suspected to be pregnant.
Patients that have planned MRI examination over the duration of the study.
Patients who have suffered recent cardiac arrest within the preceding 3 months.
Patients enrolled in another clinical study or clinical trial.
Patients on oral or IV anti-coagulation (e.g., IV heparin drip, acetylsalicylic acid , Plavix). Subcutaneous heparin or low molecular weight heparin are acceptable).